

ACR Review 2025

25-29 Octubre / #ACReview25


Lo mejor de - LES, S.Sjögren y Esclerosis Sistémica

Dra. Ana Lois Iglesias

Complejo Hospitalario Universitario de A Coruña



LES



LES: Guía

26S11: 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus

CME

IP

OD

Location: W196A-C

26S11: 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus



Location: W196A-C

Systemic Lupus Erythematosus						
HCQ (unless contraindicated)						
Glucocorticoids: Only if necessary, at lowest effective dose for shortest possible duration*			Taper to ≤5 mg/day by 6 months (ideally to zero)			
Pulse glucocorticoid for organ- and life-threatening manifestations						
Escalation of therapy (any organ system) when refractory to initial treatment						
Early introduction of immunosuppressive agents to minimize glucocorticoid toxicity*						
Mucocutaneous	Musculoskeletal	Serositis	Hematologic	Neuropsychiatric	Cardiac	Vasculitis
Sunscreen /Topicals	Arthritis	Pleuropericarditis	Leukopenia	Psychosis/seizures	Myocarditis	<ul style="list-style-type: none"> • Azathioprine • IV CYC • MPAA • Anti-CD20 • Belimumab
ACLE, SCLE, CCLE						
Mild	<ul style="list-style-type: none"> • Azathioprine • Methotrexate[§] • MPAA[±] 	Initial treatment, mild	<ul style="list-style-type: none"> • No IS treatment unless other SLE activity present 	<ul style="list-style-type: none"> • Anti-psychotic / anti-seizure therapy 	<ul style="list-style-type: none"> • IV CYC • MPAA • Anti-CD20 and/or IVIG 	<ul style="list-style-type: none"> • Anifrolumab • Belimumab
<ul style="list-style-type: none"> • Add quinacrine • Switch HCQ to CQ** 	<ul style="list-style-type: none"> • Colchicine • NSAIDs • and/or IVIG 	<ul style="list-style-type: none"> • Azathioprine • MPAA[±] • Anifrolumab • Belimumab • IL-1 blockade 	<ul style="list-style-type: none"> • MPA • Anti-CD20 • IV CYC 	<ul style="list-style-type: none"> • Optic neuritis, acute confusional state, mononeuritis multiplex 	<ul style="list-style-type: none"> • Libman-Sacks Endocarditis 	
Moderate-Severe [†]	Low threshold to add/substitute for		<ul style="list-style-type: none"> • Thrombocytopenia 	<ul style="list-style-type: none"> • Anticoagulation • IS therapy 	<ul style="list-style-type: none"> • Severe • IV CYC • Anti-CD20 	
<ul style="list-style-type: none"> • Methotrexate • MPAA • Anifrolumab • Belimumab 	<ul style="list-style-type: none"> • Anifrolumab • Belimumab 		<ul style="list-style-type: none"> • Asymptomatic <30,000 platelets/ mcl • Azathioprine • CNJ • MPAA[±] • Belimumab • Anti-CD20 and/or IVIG 	<ul style="list-style-type: none"> • Myelitis 	<ul style="list-style-type: none"> • Life-threatening • Addition of: <ul style="list-style-type: none"> • PLEX and/or IVIG 	
Refractory			<ul style="list-style-type: none"> • Symptomatic • Anti-CD20 and/or IVIG 	<ul style="list-style-type: none"> • Cognitive Dysfunction 		
• Lenalidomide			<ul style="list-style-type: none"> • Hemolytic anemia 	<ul style="list-style-type: none"> • Cognitive therapy 		
Bullous LE			<ul style="list-style-type: none"> • Symptomatic • Anti-CD20 and/or IVIG 	<ul style="list-style-type: none"> • No IS treatment 		
Mild						
• Dapsone						
Severe						
<ul style="list-style-type: none"> • Azathioprine • Methotrexate • MPAA • Anti-CD20 						
Chilblain LE						
<ul style="list-style-type: none"> • CCB • PDE5i • Pentoxifylline 						
LCV						
<ul style="list-style-type: none"> • Colchicine • Dapsone 						

■ Strong recommendation for
■ Conditional recommendation for
■ Conditional recommendation against
 *Good practice statements

OVERVIEW: Organ Specific Recommendations

Why taper to ≤ 5 mg pred/d?
Strong recommendation

GULP study:
 127 SLE pts starting pred ≥5 mg/d (w/ HCQ or IS) within 12 mo. of SLE dx (2 yr f/u)

■ +5 mg/d
■ +2.5 but <5 mg/d
■ +1.5 mg/d
■ +1 mg/d
■ +0.5 but <1 mg/d
■ 0 mg/d

• **No difference in relapse rates** (p=0.706) when tapering to <5 mg/d vs. not tapering < 5 mg/day (46.4%).

LES: Tratamientos

0650: Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results

Location: Hall F1

Abstract Poster Presenter: [Brad H. Rovin, MD](#) – The Ohio State University

FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis

2694: Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus

Location: W375C

Presenting Author: [Amit Saxena, MD, MSc](#) – NYU Grossman School of Medicine

CAR T-cell Therapy in SLE: A Systematic Review

Presenting Author: [Alberto Nordmann-Gomes, BS](#) – Columbia University Irving Medical Center

LES: Tratamientos

1547: Anifrolumab in Systemic Lupus Erythematosus with Renal Involvement: National Multicenter Registry in Clinical Practice

Location: Hall F1

Abstract Poster Presenter: [Vanesa Calvo Río, MD](#) – Hospital Universitario Marqués de Valdecilla, Immunopathology group, IDIVAL

1552: Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study

Location: Hall F1

Abstract Poster Presenter: [Zahi Touma, MD, PhD](#) – University of Toronto

1545: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study

Location: Hall F1

Abstract Poster Presenter: [Susan Manzi, MD, MPH](#) – Allegheny Health Network

0642: Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort

Location: Hall F1

Abstract Poster Presenter: [Javier Narvaez, PhD](#) – Hospital Universitario de Bellvitge

LES: Tratamientos

0855: Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial

Location: W192A-C

Presenting Author: [Jane Salmon, MD](#) – Hospital for Special Surgery

2451: Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus

Location: Hall F1

Abstract Poster Presenter: [J. Michelle Kahlenberg, MD, PhD](#) – University of Michigan

2461: Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing

 Tuesday, October 28, 2025  10:30 AM - 12:30 PM Central Time

0668: Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus

 Sunday, October 26, 2025  10:30 AM - 12:30 PM Central Time

LES (2):

Redefining When to Biopsy the Kidney in Patients with SLE

Presenting Author: Michelle Petri, MD, MPH (she/her/hers) – Johns Hopkins University School of Medicine

0839: Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking

Location: S102

Presenting Author: [Iris Tang, MBBS, MRCP](#) – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong

Session: (1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

1840: Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity

 Tuesday, October 28, 2025  10:30 AM - 12:30 PM Central Time

2401: Associations Between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis

2694: Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus

Síndrome de Sjögren



Síndrome de Sjögren: Diagnóstico

0507: Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren's disease of recent onset versus sicca controls.

Location: Hall F1

Abstract Poster Presenter: [Daniela Rojas Abarca, MD, RhMSUS](#) – Universidad Nacional Autonoma de Mexico

0513: Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies

Location: Hall F1

Abstract Poster Presenter: [Massiel Jimenez Artiles, MD \(she/her/hers\)](#) – Brown University/ Rhode Island Hospital

Síndrome de Sjögren: Diagnóstico

26S25: Tackling the Burning Question of Peripheral Neuropathies in Sjögren's Disease: New Guidelines   

Location: W181A-C

Moderator: [Jennifer King, MD, PhD](#) – UCLA

Moderator: [Dana DiRenzo, MD, RhMSUS, MHS](#) – University of Pennsylvania

Session Coordinator: [Jennifer Grossman, MD](#) – UCLA

1680: Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren's Disease: a systematic review

Location: S103

Presenting Author: [Valeria Manfrè, MD](#) – Division of Rheumatology, Department of Medicine, University of Udine, Italy

1392: Cancer Mortality in Sjogren's Disease: Disproportionate Increase in Mortality from Cancers in Sjogren's Disease Relative to All-Cancers

Location: Hall F1

Abstract Poster Presenter: [Margaret Essien, BS](#) – University of California Los Angeles

Síndrome de Sjögren: Tratamientos

2296: Evaluation of the Dual Mode of Action of linalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren's Disease: Results From a Phase 2 Mechanistic Study

Location: Hall F1

Abstract Poster Presenter: [Divi Corneic, MD, PhD \(he/him/his\)](#) – University of Brest

2300: Evaluation of the linalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren's Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study

Location: Hall F1

Abstract Poster Presenter: [sandrine jousse joulín, MD](#) – cavale blanche hospital

Esclerosis Sistémica



Esclerosis Sistémica

0682: Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study

Location: Hall F1

Abstract Poster Presenter: [Alex Luta, MD](#) – Hospital for Special Surgery

0699: A Retrospective Comparison of Transplant Outcomes in Patients with and Without Systemic Sclerosis

Location: Hall F1

Abstract Poster Presenter: [Lilit Grigoryan, DO](#) – albany medical college

1565: Association of the Gastrointestinal (GI) Microbiome and GI Symptoms in Systemic Sclerosis: An International, Multi-center, Observational Study

Location: Hall F1

Abstract Poster Presenter: [Elizabeth Volkmann, MD, MS](#) – University of California, Los Angeles

0673: Association Between Vasoactive-vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence from a EUSTAR Study

Location: Hall F1

Abstract Poster Presenter: [Cosimo Bruni, MD, PhD](#) – University of Zurich

1562: Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study

Location: Hall F1

Abstract Poster Presenter: [Cosimo Bruni, MD, PhD](#) – University of Zurich

Esclerosis Sistémica

1561: Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion

 Monday, October 27, 2025  10:30 AM - 12:30 PM Central Time

1567: Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease

 Monday, October 27, 2025  10:30 AM - 12:30 PM Central Time

0701: Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort

 Sunday, October 26, 2025  10:30 AM - 12:30 PM Central Time

Esclerosis Sistémica

2477: Current treatment Strategies in Systemic Sclerosis-Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)

Location: Hall F1

Abstract Poster Presenter: [Corrado Campochiaro, MD](#) – IRCCS San Raffaele Hospital

2476: Blinatumomab in rapid progressive systemic sclerosis

Location: Hall F1

Abstract Poster Presenter: [Christina Gebhardt, MD](#) – LMU Klinikum

1589: Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation



Monday, October 27, 2025



10:30 AM - 12:30 PM Central Time